We are a leader in the field of neuronal nicotinic receptor (NNR) chemistry and biology. Our product candidates are designed to selectively act on NNRs, an underexploited class of molecular targets, to meet unmet medical needs across a broad spectrum of therapeutic indications with large market potential, including:

Major depressive disorder Attention deficit/hyperactivity disorder Alzheimer's disease Cognitive dysfunction in schizophrenia Smoking cessation Pain Obesity Addiction Parkinson's disease Inflammation Anxiety disorders

Neuronal nicotinic receptors (NNRs)